BRPI0417910A - composto ou um sal ou salvato farmaceuticamente aceitáveis do mesmo, e, uso de um composto - Google Patents
composto ou um sal ou salvato farmaceuticamente aceitáveis do mesmo, e, uso de um compostoInfo
- Publication number
- BRPI0417910A BRPI0417910A BRPI0417910-2A BRPI0417910A BRPI0417910A BR PI0417910 A BRPI0417910 A BR PI0417910A BR PI0417910 A BRPI0417910 A BR PI0417910A BR PI0417910 A BRPI0417910 A BR PI0417910A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- hydrogen
- solvate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 abstract 2
- 229930195711 D-Serine Natural products 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003591 Ataxia Diseases 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 239000011575 calcium Chemical group 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 229910052744 lithium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Chemical group 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Chemical group 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000003955 neuronal function Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000011591 potassium Chemical group 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000011734 sodium Chemical group 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000011701 zinc Chemical group 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53297803P | 2003-12-29 | 2003-12-29 | |
| PCT/US2004/043547 WO2005066143A2 (en) | 2003-12-29 | 2004-12-28 | Benzo[d]isoxazol-3-ol daao inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0417910A true BRPI0417910A (pt) | 2007-04-10 |
Family
ID=34748836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417910-2A BRPI0417910A (pt) | 2003-12-29 | 2004-12-28 | composto ou um sal ou salvato farmaceuticamente aceitáveis do mesmo, e, uso de um composto |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7166725B2 (https=) |
| EP (1) | EP1711478A2 (https=) |
| JP (1) | JP2007534657A (https=) |
| KR (1) | KR20060128978A (https=) |
| CN (3) | CN102010382A (https=) |
| AU (1) | AU2004312511A1 (https=) |
| BR (1) | BRPI0417910A (https=) |
| CA (1) | CA2552098A1 (https=) |
| CZ (1) | CZ2006426A3 (https=) |
| IL (1) | IL176607A0 (https=) |
| NZ (1) | NZ548213A (https=) |
| PL (1) | PL380766A1 (https=) |
| RU (1) | RU2384574C2 (https=) |
| WO (1) | WO2005066143A2 (https=) |
| ZA (1) | ZA200605384B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007517056A (ja) * | 2003-12-29 | 2007-06-28 | セプラコア インコーポレーテッド | ピロール及びピラゾールｄａａｏ阻害剤 |
| CA2472806A1 (en) | 2004-05-18 | 2005-11-18 | Petro-Canada | Compositions and methods for treating turf insect pests and diseases such as fungal infestations |
| EP2455075B1 (en) | 2005-07-06 | 2018-06-20 | Sunovion Pharmaceuticals Inc. | Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine |
| NZ569608A (en) | 2006-01-06 | 2011-09-30 | Sepracor Inc | Tetralone-based monoamine reuptake inhibitors |
| US20070203111A1 (en) | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| BRPI0707989A2 (pt) | 2006-02-21 | 2011-05-17 | Toyama Chemical Co Ltd | métodos para preparar um derivado de ácido fenilpropiÈnico, um derivado de benzofenona, um derivado de 6-metil-1, 2-benzisoxazol-3(2h) -ona e ácido 2-oxo-2h-cromeno carboxìlico, derivado de 6-(halometil) -1, 2-benzisoxazol-3(2h) -ona, e, derivado de benzofenona ou um sal do mesmo |
| CN101421228B (zh) | 2006-03-31 | 2014-05-21 | 塞普拉柯公司 | 手性酰胺和胺的制备 |
| US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US20080082066A1 (en) * | 2006-10-02 | 2008-04-03 | Weyerhaeuser Co. | Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks |
| US9357768B2 (en) | 2006-10-05 | 2016-06-07 | Suncor Energy Inc. | Herbicidal composition with increased herbicidal efficacy |
| CA2676432A1 (en) | 2007-01-18 | 2008-07-24 | Sepracor, Inc. | Inhibitors of d-amino acid oxidase |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| CA2688493C (en) | 2007-05-31 | 2016-04-19 | Sepracor Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
| JP5596678B2 (ja) | 2008-06-26 | 2014-09-24 | サンコー エナジー インコーポレーテッド | 顔料を含む改善された芝草用殺菌製剤 |
| US20100120740A1 (en) * | 2008-08-07 | 2010-05-13 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| CN102292094B (zh) | 2009-01-20 | 2013-08-14 | 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 | 增强神经药方疗效的山梨酸与苯甲酸及其衍生物 |
| US20110034434A1 (en) * | 2009-08-07 | 2011-02-10 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| CN103338642A (zh) | 2010-09-09 | 2013-10-02 | 桑科能源股份有限公司 | 协同作用的石蜡油和啶酰菌胺杀真菌剂 |
| WO2013181738A1 (en) | 2012-06-04 | 2013-12-12 | Suncor Energy Inc. | Formulations containing paraffinic oil and anti-settling agent |
| US9505753B2 (en) | 2012-08-08 | 2016-11-29 | The Johns Hopkins University | Inhibitors of D-amino acid oxidase |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| CN103435561B (zh) * | 2013-08-19 | 2016-08-10 | 上海交通大学 | 一种新型d-氨基酸氧化酶抑制剂及其制备和应用 |
| KR20160029837A (ko) * | 2014-03-24 | 2016-03-15 | 가오슝 창 궁 메모리얼 하스피털 | 치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도 |
| CN105801511B (zh) * | 2016-04-22 | 2018-01-02 | 山西大学 | 一种1,2‑苯并异恶唑啉‑3‑酮的制备方法 |
| ES2936094T3 (es) | 2016-06-13 | 2023-03-14 | Syneurx Int Taiwan Corp | Cocristales de benzoato de sodio y usos de los mismos |
| RU2765625C2 (ru) | 2016-06-13 | 2022-02-01 | Сайньюрекс Интернэшнл (Тайвань) Корп. | Сокристаллы бензоата лития и их применения |
| CA2938096C (en) | 2016-08-04 | 2019-02-26 | Suncor Energy Inc. | Stabilized emulsions |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| JP6550426B2 (ja) * | 2017-07-26 | 2019-07-24 | カオシュン・チャン・グン・メモリアル・ホスピタル | 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 |
| WO2019043635A1 (en) | 2017-09-01 | 2019-03-07 | Richter Gedeon Nyrt. | COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE |
| US10336724B2 (en) * | 2017-10-18 | 2019-07-02 | Syneurx International (Taiwan) Corp. | D-amino acid oxidase inhibitors and therapeutic uses thereof |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| BR112021014592A2 (pt) | 2019-01-25 | 2021-10-05 | Suncor Energy Inc. | Compostos fotosensibilizadores, métodos de fabricação e aplicação em plantas |
| AU2020222515B2 (en) | 2019-02-15 | 2025-10-09 | Nutrien Ag Solutions (Canada) Inc. | The use of protoporphyrin IX derivatives to improve the health of plants |
| CN117362246B (zh) * | 2023-12-04 | 2024-03-12 | 烟台海川化学制品有限公司 | 一种3-苯基-1,4,2-二恶唑-5-酮的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58177915A (ja) * | 1982-04-12 | 1983-10-18 | Green Cross Corp:The | 抗血栓剤 |
| US4738709A (en) | 1985-01-10 | 1988-04-19 | Ppg Industries, Inc. | Herbicidally active substituted benzisoxazoles |
| JPH0477476A (ja) | 1990-07-19 | 1992-03-11 | Sankyo Co Ltd | 抗潰瘍剤 |
| AU674358B2 (en) | 1992-10-28 | 1996-12-19 | Toyama Chemical Co. Ltd. | Novel 1,2-benzoisoxazole derivative or its salt and brain -protecting agent comprising the same |
| HU221138B1 (en) | 1994-08-30 | 2002-08-28 | Sankyo Co | Condensed isoxazolyloxy- and -thioalkylamine derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| US5484763A (en) | 1995-02-10 | 1996-01-16 | American Cyanamid Company | Substituted benzisoxazole and benzisothiazole herbicidal agents |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| DE19960917A1 (de) * | 1999-12-17 | 2001-06-21 | Bayer Ag | Neue 3-Oxo-2,1-benzisoxazol-1(3H)-carboxamide zur Behandlung von ZNS-Erkrankungen |
| JP2001247462A (ja) | 2000-03-07 | 2001-09-11 | Otsuka Pharmaceut Co Ltd | ウレアーゼ阻害剤 |
| US20070197610A1 (en) | 2004-03-16 | 2007-08-23 | Janssen Pharmaceutica N.V. | Benzisoxazoles |
-
2004
- 2004-12-28 CN CN2010105590539A patent/CN102010382A/zh active Pending
- 2004-12-28 AU AU2004312511A patent/AU2004312511A1/en not_active Abandoned
- 2004-12-28 ZA ZA200605384A patent/ZA200605384B/en unknown
- 2004-12-28 RU RU2006127436/04A patent/RU2384574C2/ru not_active IP Right Cessation
- 2004-12-28 PL PL380766A patent/PL380766A1/pl not_active Application Discontinuation
- 2004-12-28 CA CA002552098A patent/CA2552098A1/en not_active Abandoned
- 2004-12-28 CN CN2004800422050A patent/CN1922157B/zh not_active Expired - Fee Related
- 2004-12-28 EP EP04815603A patent/EP1711478A2/en not_active Withdrawn
- 2004-12-28 WO PCT/US2004/043547 patent/WO2005066143A2/en not_active Ceased
- 2004-12-28 CN CN201010150424A patent/CN101798291A/zh active Pending
- 2004-12-28 CZ CZ20060426A patent/CZ2006426A3/cs unknown
- 2004-12-28 US US11/024,151 patent/US7166725B2/en not_active Expired - Lifetime
- 2004-12-28 KR KR1020067015383A patent/KR20060128978A/ko not_active Ceased
- 2004-12-28 BR BRPI0417910-2A patent/BRPI0417910A/pt not_active Application Discontinuation
- 2004-12-28 NZ NZ548213A patent/NZ548213A/en unknown
- 2004-12-28 JP JP2006547443A patent/JP2007534657A/ja active Pending
-
2006
- 2006-06-28 IL IL176607A patent/IL176607A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL176607A0 (en) | 2006-10-31 |
| CN1922157B (zh) | 2011-01-12 |
| CN1922157A (zh) | 2007-02-28 |
| US7166725B2 (en) | 2007-01-23 |
| US20050143434A1 (en) | 2005-06-30 |
| ZA200605384B (en) | 2007-10-31 |
| CA2552098A1 (en) | 2005-07-21 |
| NZ548213A (en) | 2010-05-28 |
| JP2007534657A (ja) | 2007-11-29 |
| RU2384574C2 (ru) | 2010-03-20 |
| PL380766A1 (pl) | 2007-03-19 |
| RU2006127436A (ru) | 2008-02-10 |
| KR20060128978A (ko) | 2006-12-14 |
| AU2004312511A1 (en) | 2005-07-21 |
| CN102010382A (zh) | 2011-04-13 |
| EP1711478A2 (en) | 2006-10-18 |
| CN101798291A (zh) | 2010-08-11 |
| CZ2006426A3 (cs) | 2006-10-11 |
| WO2005066143A2 (en) | 2005-07-21 |
| WO2005066143A3 (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0417910A (pt) | composto ou um sal ou salvato farmaceuticamente aceitáveis do mesmo, e, uso de um composto | |
| BRPI0418244A (pt) | composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica | |
| BR0013667A (pt) | Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos | |
| BRPI0410979A (pt) | composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| BRPI0417687A (pt) | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade | |
| DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| BR0211810A (pt) | Derivados ácido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo | |
| CY1108583T1 (el) | Μεθοδος για θεραπεια σοβαρης καρδιακης ανεπαρκειας και φαρμακο για αυτη | |
| PT828724E (pt) | Diaril-5-oxigenadas-2-(5h)-furanonas comoinibidoras de cox-2 | |
| BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
| BR0309553A (pt) | Composto ou sal farmaceuticamente aceitável ou éster ou amida hidrolisável in vivo deste, processo para prepará-lo, composição farmacêutica, uso do composto, e, métodos para produzir um efeito inibidor de hdac em um animal de sangue quente, e para tratar câncer em um animal de sangue quente | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| KR890005031A (ko) | L-도파유도체 또는 그의 산부가염, 그의 제조방법 및 그의 용도 | |
| BRPI0410316A (pt) | composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores | |
| CY1109376T1 (el) | Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης | |
| BR0307588A (pt) | Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença | |
| ATE270550T1 (de) | Wirkstoff zum schutz für organ oder gewebe | |
| EA200800303A1 (ru) | Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами | |
| BRPI0518231A2 (pt) | derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica | |
| BRPI0509512A (pt) | método de tratar esquizofrenia e/ou anormalidades glicorregulatórias | |
| MA27056A1 (fr) | Derives d'azolylcarbinols d'aryle (ou d'heteroaryle) pour le traitement de l'incontinence d'urine. | |
| MXPA05013607A (es) | Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos. | |
| CA1330446C (en) | Phenolic thioalkylamides as inhibitors of 5-lipoxygenase | |
| ATE451922T1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |